| Follow Us: Facebook Twitter Youtube RSS Feed

Innovation & Job News

ScarX Therapeutics receives $250,000 investment

It's not the most pressing medical issue, but it's one that affects almost all of us at some point in our lives: post-surgical scarring. It's not just an aesthetic concern -- though in cases like the treatment of burns, the disfiguring effects of scarring can be life-altering -- since scarring can be painful and, depending on its location on the body, also inhibit movement. A local startup called ScarX Therapeutics is working on commercializing a new treatment for post-surgical scarring, and it's just received a $250,000 cash infusion to help things along.

The investment comes courtesy of the Ontario Centres of Excellence, a non-profit research accelerator funded by the provincial government. It's the first award distributed through Ontario's recently expanded market readiness program. It will allow ScarX to begin clinical trials later this year.

The topical treatment, a cream patients would apply themselves, emerged from research done by Hospital for Sick Children scientist Dr. Benjamin Alman. His work (which has also been supported by MaRS Innovation) actually focused on a rare type of tumour originally, until he realized that a pain-relief treatment he'd come across in the course of that research had the effect of diminishing scar formation. He's still hoping that after the scar treatment, which could serve a much wider group of patients, is finished, the molecule in question can be developed into a treatment for that tumour as well.

Writer: Hamutal Dotan
Source: Ontario Centres of Excellence
Signup for Email Alerts
Signup for Email Alerts

Related Content